BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Awasthi S, Hook LM, Swaminathan G, Cairns TM, Brooks B, Smith JS, Ditto NT, Gindy ME, Bett AJ, Espeseth AS, Cohen GH, Friedman HM. Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants. Vaccine 2019;37:3770-8. [PMID: 31153687 DOI: 10.1016/j.vaccine.2019.05.068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Brooks BD, Beland A, Aguero G, Taylor N, Towne FD. Moving beyond Titers. Vaccines 2022;10:683. [DOI: 10.3390/vaccines10050683] [Reference Citation Analysis]
2 Hook LM, Awasthi S, Cairns TM, Alameh M, Fowler BT, Egan KP, Sung MMH, Weissman D, Cohen GH, Friedman HM. Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine. Viruses 2022;14:540. [DOI: 10.3390/v14030540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Alameh MG, Tombácz I, Bettini E, Lederer K, Sittplangkoon C, Wilmore JR, Gaudette BT, Soliman OY, Pine M, Hicks P, Manzoni TB, Knox JJ, Johnson JL, Laczkó D, Muramatsu H, Davis B, Meng W, Rosenfeld AM, Strohmeier S, Lin PJC, Mui BL, Tam YK, Karikó K, Jacquet A, Krammer F, Bates P, Cancro MP, Weissman D, Luning Prak ET, Allman D, Locci M, Pardi N. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 2021;54:2877-2892.e7. [PMID: 34852217 DOI: 10.1016/j.immuni.2021.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
4 Batty CJ, Heise MT, Bachelder EM, Ainslie KM. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Adv Drug Deliv Rev 2021;169:168-89. [PMID: 33316346 DOI: 10.1016/j.addr.2020.12.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 37.0] [Reference Citation Analysis]
5 Prior JT, Davitt C, Kurtz J, Gellings P, McLachlan JB, Morici LA. Bacterial-Derived Outer Membrane Vesicles are Potent Adjuvants that Drive Humoral and Cellular Immune Responses. Pharmaceutics 2021;13:131. [PMID: 33498352 DOI: 10.3390/pharmaceutics13020131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
6 Egan KP, Hook LM, Naughton A, Pardi N, Awasthi S, Cohen GH, Weissman D, Friedman HM. An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection. PLoS Pathog 2020;16:e1008795. [PMID: 32716975 DOI: 10.1371/journal.ppat.1008795] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
7 Awasthi S, Hook LM, Pardi N, Wang F, Myles A, Cancro MP, Cohen GH, Weissman D, Friedman HM. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci Immunol 2019;4:eaaw7083. [PMID: 31541030 DOI: 10.1126/sciimmunol.aaw7083] [Cited by in Crossref: 28] [Cited by in F6Publishing: 41] [Article Influence: 14.0] [Reference Citation Analysis]
8 Egan K, Hook LM, LaTourette P, Desmond A, Awasthi S, Friedman HM. Vaccines to prevent genital herpes. Transl Res 2020;220:138-52. [PMID: 32272093 DOI: 10.1016/j.trsl.2020.03.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]